Phase I Study of pTTL T Cell Immunotherapy in Patients with Advanced Colorectal Cancer

The primary objective of this study is to evaluate the safety and tolerability of the novel T cell immunotherapy, **pTTL**, in patients with advanced **colorectal cancer**. This is clinically relevant as it aims to determine the potential of pTTL as a therapeutic option for a condition with limited treatment alternatives, potentially improving patient outcomes and expanding available therapeutic strategies.

The clinical trial involves participants diagnosed with **colorectal cancer**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial population is noted to include a vulnerable population, although specific details regarding the selection process or lifestyle considerations such as diet, physical activity, or habits are not provided. The sponsor has not disclosed the total number of participants involved in the study. Key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed to evaluate the safety and efficacy of a novel T cell immunotherapy, pTTL, in patients with advanced **colorectal cancer**. This is a Phase 1 trial, which is the initial phase in clinical research, focusing on assessing the safety profile of the investigational therapy. The trial employs a randomized, double-blind, and controlled design to ensure unbiased results and to compare the effects of the investigational therapy against a control. The estimated duration of the trial spans from April 5, 2023, to October 5, 2029, allowing for comprehensive data collection and analysis over a six-year period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be enrolled in the trial and randomized to receive either the investigational therapy or a control. Throughout the trial, participants will attend regular follow-up visits, which are scheduled to monitor safety, collect data on therapeutic effects, and manage any adverse events. These visits are integral to ensuring participant safety and the integrity of the trial data.

The end-of-study visit marks the conclusion of a participant's involvement in the trial. During this visit, final assessments are conducted to evaluate the long-term effects of the therapy and to gather comprehensive data for analysis. The expected length of participant involvement varies, depending on individual response and the occurrence of any adverse events. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the investigator. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial may focus solely on the experimental medication without a comparator or placebo group.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is April 5, 2023, with an anticipated end date of October 5, 2029. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. The trial will likely employ standardized methods for measuring and collecting data, which may include validated scales, laboratory tests, or patient-reported outcomes, depending on the investigational product and disease context. The analysis of efficacy data will be conducted in accordance with the trial's protocol, ensuring rigorous and scientifically sound conclusions. The absence of detailed endpoints suggests that the primary focus may be on safety and tolerability, with efficacy assessments providing supportive information for future trial phases.